Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.
Ver gráficos interativos e demonstrações completas → Modelo de avaliação (DCF) →
| Demonstração de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receita total | $3.4B | $2.9B | $2.4B | $1.9B | $1.5B | $1.1B | $1.0B | $788M | $451M | $162M | $15M | $20M | $0M | $3M | $53M | $77M | $34M | $3M | $4M | $1M | $39M |
| Lucro bruto | $3.3B | $2.8B | $2.3B | $1.8B | $1.5B | $1.1B | $1.0B | $781M | $446M | $160M | $15M | $20M | ($14M) | ($11M) | $42M | $77M | $34M | $3M | $4M | $1M | $39M |
| Margem Bruta % | 98.0% | 98.2% | 98.6% | 97.9% | 98.4% | 98.7% | 99.0% | 99.1% | 98.9% | 99.2% | 100.0% | 100.0% | — | -372.8% | 78.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Resultado Operacional (EBIT) | $789M | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | ($131M) | ($147M) | ($94M) | ($64M) | ($50M) | $1M | $34M | ($14M) | ($54M) | ($87M) | ($212M) | ($113M) |
| % de margem operacional | 23.4% | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | -476.5% | — | -1701.9% | 2.7% | 43.8% | -41.0% | -1817.5% | -2196.2% | -17340.0% | -288.8% |
| Resultado líquido | $706M | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | ($143M) | ($141M) | ($89M) | ($61M) | ($46M) | $5M | $38M | ($8M) | ($51M) | ($89M) | ($207M) | ($107M) |
| Margem Líquida % | 20.9% | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% | -449.8% | — | -1579.0% | 9.5% | 48.5% | -23.8% | -1728.3% | -2229.3% | -16936.2% | -273.2% |
| EBITDA | — | $667M | $640M | $416M | $265M | $138M | $148M | $86M | $41M | ($121M) | ($140M) | ($88M) | ($64M) | ($49M) | $2M | $35M | ($12M) | ($48M) | ($74M) | ($203M) | ($103M) |
| Lucro por ação (EPS) | $6.84 | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | $-0.69 | $0.08 | $0.67 | $-0.15 | $-1.30 | $-2.30 | $-5.45 | $-2.84 |
| Ações em circulação (M) | — | 102M | 104M | 101M | 99M | 98M | 98M | 96M | 95M | 88M | 87M | 84M | 75M | 67M | 67M | 56M | 53M | 39M | 38M | 38M | 38M |
Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.
Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de NBIX. /companies/us/NBIX
As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.
About TickerBase · Data methodology & sources · Privacy · Terms